These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 20088680)
1. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide. Zheng Z; Aojula H; Clarke D J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680 [TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. Li R; Wu R; Zhao L; Wu M; Yang L; Zou H ACS Nano; 2010 Mar; 4(3):1399-408. PubMed ID: 20148593 [TBL] [Abstract][Full Text] [Related]
4. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167 [TBL] [Abstract][Full Text] [Related]
5. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
6. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877 [TBL] [Abstract][Full Text] [Related]
7. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559 [TBL] [Abstract][Full Text] [Related]
8. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
9. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Ji BS; He L J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197 [TBL] [Abstract][Full Text] [Related]
10. Reversal of cancer multidrug resistance by green tea polyphenols. Mei Y; Qian F; Wei D; Liu J J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646 [TBL] [Abstract][Full Text] [Related]
11. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326 [TBL] [Abstract][Full Text] [Related]
12. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
15. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Arora A; Seth K; Kalra N; Shukla Y Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829 [TBL] [Abstract][Full Text] [Related]
16. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799 [TBL] [Abstract][Full Text] [Related]
17. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169 [TBL] [Abstract][Full Text] [Related]
18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
19. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Shen J; Zhang W; Wu J; Zhu Y Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591 [TBL] [Abstract][Full Text] [Related]
20. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]